Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab

Journal of Occupational and Environmental Medicine

Volumn 52, Issue 6, 2010, Pages 618-621

  Herenius, Marieke M J ^a   Hoving, Jan L ^a   Sluiter, Judith K ^a   Raterman, Hennie G ^b   Lems, Willem F ^b   Dijkmans, Ben A C ^b,c   Tak, Paul Peter ^a   Nurmohamed, Mike T ^c   Voskuyl, Alexandre E ^b   Frings Dresen, Monique H W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CHECKLIST; CONTROLLED STUDY; DRUG SUBSTITUTION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RATING SCALE; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; WORK CAPACITY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; DISABILITY; MIDDLE AGED; PATHOPHYSIOLOGY; PRODUCTIVITY; PROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISABILITY EVALUATION; EFFICIENCY; FATIGUE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TUMOR NECROSIS FACTORS;

EID: 77954029763     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181de8357     Document Type: Article

References (40)

1. Wolfe F, Hawely DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25:2108-2117.
2. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, van Albada-Kuipers GA, Hofman DM, Bijlsma JW. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol. 1998;37:848-853.
3. Doeglas D, Suurmeijer T, Krol B, Sanderman R, van LM, van RM. Work disability in early rheumatoid arthritis. Ann Rheum Dis. 1995;54:455-460.
4. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006;56:18-27.
5. Verstappen SM, Bijlsma JW, Verkleij H, et al. Utrecht Rheumatoid Arthritis Cohort Study Group. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum. 2004;51:488-497.
6. de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings- Dresen MH. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004;63:1362-1367.
7. Smolen JS, Han C, van der HD, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54:716-722.
8. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:3046-3054.
9. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66 Suppl 3:iii2-iii22.
10. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
11. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
12. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
13. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:838-846.
14. Hulsemann JL, Mittendorf T, Merkesdal S, et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis. 2005;64:1456-1461.
15. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:1169-1175.
16. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2000;39:28-33.
17. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 2004;71:518-524.
18. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol. 2007;34:2211-2217.
19. Hoving JL, Bartelds GM, Sluiter JK, et al. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol. 2009;38:246-250.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
21. Ilmarinen J, Tuomi K. Work Ability Index for Ageing Workers. In: Ilmarinen J, ed. Ageing and Work. Helsinki: Finnish Institute of Occupational Health; 1993:142-151.
22. Tuomi K, Ilmarinen J, Jakhola A, Katajrinne L, Tulkki A. Work Ability Index. Helsinki: Finnish Institute of Occupational Health; 1998.
23. de Croon EM, Sluiter JK, Nijssen TF, et al. Work ability of Dutch employees with rheumatoid arthritis. Scand J Rheumatol. 2005;34:277-283.
24. Sluiter JK, Frings-Dresen MH. Quality of life and illness perception in working and sick-listed chronic RSI patients. Int Arch Occup Environ Health. 2008;81:495-501.
25. Tijhuis GJ, de JZ, Zwinderman AH, et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology (Oxford). 2001;40:1112-1119.
26. Beurskens AJ, Bultmann U, Kant I, Vercoulen JH, Bleijenberg G, Swaen GM. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med. 2000;57:353-357.
27. Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ. Tailored cognitivebehavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain. 2002;100:141-153.
28. van Veldhoven M, Broersen S. Measurement quality and validity of the "need for recovery scale." Occup Environ Med. 2003;60 Suppl 1:i3-i9.
29. Prevoo ML, Van't Hof MA, Kuper HH, van Leeuwen MA, van De Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38;44-48.
30. Bombardier C, Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control Clin Trials. 1991;12;243S-256S.
31. van Veldhoven M. Psychosociale arbeidsbelasting en werkstresss. Thesis. Lisse, The Netherlands: Swets & Zeitlinger; 1996.
32. Weijman I, Ros WJ, Rutten GE, Schaufeli WB, Schabracq MJ, Winnubst JA. Fatigue in employees with diabetes: its relation with work characteristics and diabetes related burden. Occup Environ Med. 2003;60 Suppl 1:i93-i98.
33. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729-740.
34. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol. 2005;32:2250-2256. (Pubitemid 41587877)
35. van Gestel AM, Prevoo ML, Van't Hof MA, van Rijswijk MH, van De Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
36. Nieuwenhuijsen K, Verbeek JH, de Boer AG, Blonk RW, van Dijk FJ. Predicting the duration of sickness absence for patients with common mental disorders in occupational health care. Scand J Work Environ Health. 2006; 32:67-74.
37. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. Arthritis Rheum. 2008;59:510-514. (Pubitemid 351563533)
38. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol. 2008;35:206-215.
39. Puolakka K, Kautiainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52:36-41.
40. Welsing PM, Landewe RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004;50:2082-2093.